Open an account

Vor Biopharma

VOR · NASDAQ

$19.03+$0.99 (+5.49%)TodayMarket closed ·
Prev close $18.04

About VOR

Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. The company is headquartered in Boston, Massachusetts and currently employs 76 full-time employees. The company went IPO on 2021-02-05. The firm is focused on rapidly advancing telitacicept, a dual-target fusion protein, through Phase III clinical development and commercialization to address serious autoantibody-driven conditions worldwide. Telitacicept is an investigational recombinant fusion protein designed to treat autoimmune diseases by selectively inhibiting BLyS (BAFF) and APRIL - two cytokines essential to B cell and plasma cell survival. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology. Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). A global Phase III clinical trial in gMG is underway across the United States, Europe, and South America to support potential approval in the United States and Europe.

Employees
76
Headquarters
Boston, Massachusetts
Listed
Feb 5, 2021
Sector
Health Care
Industry
Biotechnology
Website
vorbio.com

VOR key statistics

Market cap
1.07B
Price-earnings ratio
0.10
Dividend yield
—
Average volume
1.16M
Volume
796.01K
Open price
$18.06
High today
$19.55
Low today
$18.00
52 Week high
$30.40
52 Week low
$6.50

Vor Biopharma (VOR) at a glance

Vor Biopharma (VOR) last traded at $19.03, with a market cap of 1.07B and a price-to-earnings ratio of 0.10.

Today the stock has traded between $18.00 and $19.55. The current price is 5.7% above the day's low and 2.7% below its high.

Volume so far is 796.01K shares, below the average of 1.16M shares a day.

Over the past year Vor Biopharma has ranged from $6.50 to $30.40, and now sits 52% of the way up that range.

Vor Biopharma met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q2 FY26 it reported -$1.16 per share against an estimate of -$0.7113.

The average analyst price target is $39.78, 109.0% above the current price, from 7 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

86%of 7 analyst ratings say Buy
  • Buy85.7%
  • Hold14.3%
  • Sell0.0%
Price target · 9 analystsAvg $39.78
Low
$27.27
Now
$19.03
High
$52.50

VOR earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 813.4% on average.

  1. Q3 FY24: reported -$8.00 per share against an estimate of -$8.12
  2. Q4 FY24: reported -$8.80 per share against an estimate of -$5.77
  3. Q1 FY25: reported -$5.20 per share against an estimate of -$4.62
  4. Q2 FY25: reported -$43.80 per share against an estimate of -$8.86
  5. Q3 FY25: reported -$3.33 per share against an estimate of -$3.28
  6. Q4 FY25: reported $25.84 per share against an estimate of -$1.69
  7. Q1 FY26: reported -$5.11 per share against an estimate of -$0.7882
  8. Q2 FY26: reported -$1.16 per share against an estimate of -$0.7113

VOR news

  • 12 Health Care Stocks Moving In Monday's After-Market Session

  • Market-Moving News for December 9th

  • Avi Kapoor

    Dow Gains More Than 300 Points; Energy Vault Holdings Shares Jump

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • Vandana Singh

    Vor Biopharma Secures $100 Million Offering After Reporting Efficacy In Kidney Disease Trial

  • Avi Kapoor

    US Stocks Mixed; Sea Shares Gain After Q3 Results

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • Avi Kapoor

    Why Rocket Lab Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket

Similar companies

Companies in the same industry as Vor Biopharma

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.